Scancell plans Neuphoria merger; AstraZeneca wins EU nod for cancer drug

cancer drugPositive

AI Analysis

Summary

Scancell plans to merge into Neuphoria Therapeutics and take over its Nasdaq listing, changing the ticker to SCLT with up to $89 million in equity financing. AstraZeneca has won EU regulatory approval for a cancer drug.

Outcome Details

Scancell plans to merge into Neuphoria Therapeutics' Nasdaq listing and change ticker to SCLT

Importance:7/10

Sentiment:

0.40

M&Amergerlistingticker_changeregulatory_approvalcancer

Related Companies

$SCLP.L $NEUP $AZN

Read the original article

Published by Endpoints News on July 23, 2026 2:47 PM

Read Original